Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630963 · ClinicalTrials.gov registry record
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
A clinical trial of Major Depressive Disorder, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- 228
- Enrollment target
- 1
- Study location
NCT05630963: Recruiting study of Major Depressive Disorder, sponsored by Mclean Hospital.
NCT05630963 is a study of Major Depressive Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 228 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05630963, a study of Major Depressive Disorder, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- 228 participants
- Enrollment target
- 1
- Study location
Study Summary
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Primary Outcome
For assessing psychological state
Conditions Studied
Interventions
- DEVICE Aversive stimuli
- DRUG PET radiotracer
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2027-02-28 |
What NCT05630963 shows while recruiting
NCT05630963 is an observational study that tracks outcomes without assigning an intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Aversive stimuli is the first listed.
NCT05630963 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05630963 about?
NCT05630963 is a clinical study titled "Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression". This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. In...
What is the current status of trial NCT05630963?
This trial is currently recruiting. The enrollment target is 228 participants. The study started on 2021-12-29. Estimated completion is 2027-02-28.
What conditions does trial NCT05630963 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05630963?
The interventions under investigation include: Aversive stimuli (DEVICE), PET radiotracer (DRUG).
Who is sponsoring clinical trial NCT05630963?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630963 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05630963's enrollment target sits among peer trials
228 67th of 282 higher than 216 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
- NCT06116422 · 228 participants · NA
Nutrition and Obesity in Under-Represented Populations: Food Insecurity Research to Advance Science and Improve Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI